Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent liver condition affecting up to a quarter of the global population. It is characterized by accumulation of fat in the liver, not caused by excessive alcohol consumption. This article provides a concise overview of its causes, symptoms, and modern therapeutic approaches.
The exact cause of NAFLD remains uncertain. However, it is commonly associated with metabolic syndrome, which includes conditions such as obesity, type 2 diabetes, and dyslipidemia. Genetic predisposition and certain lifestyle factors, such as poor diet and lack of physical activity, also contribute to the development of NAFLD.
NAFLD is often asymptomatic in its early stages, making it difficult to diagnose. When symptoms do occur, they may include fatigue, discomfort in the upper right abdomen, and unexplained weight loss. In more advanced stages, NAFLD can progress to non-alcoholic steatohepatitis (NASH), cirrhosis, or liver cancer, presenting more severe symptoms.
There is currently no specific drug approved for NAFLD. The primary approach to management is lifestyle modification, including diet changes and increased physical activity. Pharmacological interventions are used to manage associated conditions, such as diabetes and hyperlipidemia. Emerging therapies, including novel anti-diabetic drugs and agents targeting inflammation and fibrosis, are under investigation.
NAFLD is a complex and prevalent condition, often associated with metabolic syndrome. Despite its asymptomatic nature in early stages, it can lead to serious liver complications if left untreated. While lifestyle modification remains the cornerstone of management, the search for effective drug therapies continues. Understanding the causes and symptoms of NAFLD is crucial for early detection and intervention, ultimately improving patient outcomes.
1.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
2.
Black Canadians Face Multiple Barriers to Blood Donation
3.
Stop Calling It Cancer; The Alcohol Paradox; Rural Patients Lose Ground in Screening
4.
Experts say oncology, primary care coordination necessary for best cancer patient outcomes
5.
Neural networks and label-free microscopy enable accurate detection of pancreatic tumors
1.
Machine Learning in Hematology: Boosting Diagnostic Precision and Speed in Medical Practice
2.
Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations
3.
Clinical Frameworks in Hematology for Better Care
4.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
5.
The Benefits of Understanding Haptoglobin High: What You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation